Publication
Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience
| dc.contributor.author | Silva, Joana | |
| dc.contributor.author | Falcão, Daniela | |
| dc.contributor.author | Cardoso, Cláudia | |
| dc.contributor.author | Pires, Ana Luísa | |
| dc.contributor.author | Araújo, António | |
| dc.contributor.author | Castro-Poças, Fernando | |
| dc.date.accessioned | 2023-12-21T11:19:24Z | |
| dc.date.available | 2023-12-21T11:19:24Z | |
| dc.date.issued | 2021-12 | |
| dc.description.abstract | Introduction and objectives: Immune Checkpoint Inhibitors (ICI) have shifted the paradigm of cancer therapy treatment. Despite their efficacy, ICIs may induce immune-related adverse events (irAE), which can affect various organs, namely the liver. This study intends to perform a comprehensive clinical description of the hepatic irAEs associated with ICI in a Portuguese population of a tertiary hospital centre. Materials and methods: A retrospective analysis of patients who developed immune-mediated liver injury (IMLI), among a cohort of patients treated with ICIs between March 15th of 2015 and December 15th of 2019 in a tertiary hospital. We used both Common Terminology Criteria for Adverse Events (CTCAE) and Drug-Induced Liver Injury Network (DILIN) criteria to define liver injury. Results: Among 151 patients, eight (5.3%) patients developed liver injury grade ≥3, of which five had hepatic metastasis. As such, only 3 cases were classified as IMLI. All IMLI presented with cholestasis pattern; the median duration from ICI initiation to IMLI was 84 days and/or 4 ICI cycles; one patient registered IMLI one month after nivolumab suspension; all were treated with steroids and one was successfully submitted to ICI re-challenge; a favourable outcome was seen in all patients; the median time to hepatic biochemistries normalization was 150 days. Among 10 patients with previous hepatic conditions, only one developed liver injury grade 2. Conclusions: Clinically significant ICI-related hepatotoxicity was uncommon; Immune-mediated liver injury may present a cholestatic pattern predominance. There was a low rate of liver injury of any kind in patients with previous hepatic disease while on ICI. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | da Silva JA, Falcão D, Cardoso C, Pires AL, Araújo A, Castro-Poças F. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience. Ann Hepatol. 2021;26:100561. doi:10.1016/j.aohep.2021.100561 | pt_PT |
| dc.identifier.doi | 10.1016/j.aohep.2021.100561 | pt_PT |
| dc.identifier.issn | 1665-2681 | |
| dc.identifier.uri | http://hdl.handle.net/10400.16/2897 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Elsevier | pt_PT |
| dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S166526812100260X?via%3Dihub | pt_PT |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | pt_PT |
| dc.subject | Drug Induced Liver Injury | pt_PT |
| dc.subject | Drug-Related Side Effects and Adverse Reactions | pt_PT |
| dc.subject | Hepatotoxicity | pt_PT |
| dc.subject | Immune-related adverse event | pt_PT |
| dc.subject | Immunotherapy | pt_PT |
| dc.subject | cancer | pt_PT |
| dc.title | Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.conferencePlace | Mexico | pt_PT |
| oaire.citation.startPage | 100561 | pt_PT |
| oaire.citation.title | Annals of Hepatology | pt_PT |
| oaire.citation.volume | 26 | pt_PT |
| person.familyName | Silva | |
| person.givenName | Joana | |
| person.identifier.orcid | 0000-0003-4065-2102 | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isAuthorOfPublication | 08d33369-30b0-426e-a79c-532239f174e9 | |
| relation.isAuthorOfPublication.latestForDiscovery | 08d33369-30b0-426e-a79c-532239f174e9 |